Compare FENG & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FENG | ENLV |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 26.6M |
| IPO Year | 2011 | 1995 |
| Metric | FENG | ENLV |
|---|---|---|
| Price | $2.03 | $0.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 2.5K | ★ 11.5M |
| Earning Date | 11-12-2025 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,947,410.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.17 | N/A |
| 52 Week Low | $1.28 | $0.83 |
| 52 Week High | $3.65 | $2.10 |
| Indicator | FENG | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 43.10 |
| Support Level | $2.01 | $0.89 |
| Resistance Level | $2.08 | $1.25 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 13.33 | 5.26 |
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.